Entera Bio Ltd. (ENTX)
$3.03-$0.05 (-1.62%) Today
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 17 | 1,958,117 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
35 Form 4 filings on record, the earliest from Oct 4, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Haya Taitel - Director | Grant or award | Ordinary Shares, par value NIS 0.0000769 per share | 7,278 | $0.00 | - | |
| Sean Ellis - Director | Grant or award | Ordinary Shares, par value NIS 0.0000769 per share | 7,466 | $0.00 | - | |
| Yonatan Malca - Director | Grant or award | Ordinary Shares, par value NIS 0.0000769 per share | 8,639 | $0.00 | - | |
| Gerald M. Ostrov - Director | Grant or award | Ordinary Shares, par value NIS 0.0000769 per share | 8,452 | $0.00 | - | |
| Gerald M. Lieberman - Director | Grant or award | Ordinary Shares, par value NIS 0.0000769 per share | 11,269 | $0.00 | - |
This is as far as the anonymous view goes. Create a free account for all 35 ENTX filings on record.
Entera Bio Ltd. (ENTX) had 10 insider filings in the last 90 days, with the most recent on 2026-08-07. The full record for ENTX runs to 35 Form 4 filings, the earliest from 2024-10-04. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ENTX were filed in the last 90 days. 8 purchases are on record for this company.
No insider sales of ENTX were filed in the last 90 days.
This page tracks ENTX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ENTX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
